TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22612662
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (20 IU in 500 mL)
Study: 28723852
Drug: Skin barrier
Normalized name: Skin Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin barrier cream
Study: 22751603
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg
Study: 25011986
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) treatment
Study: 27894373
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2 g/day for 24 weeks
Study: 24375837
Drug: PPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI treatment (14 days enteral omeprazole)
Study: 20181679
Drug: Combined aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined aspirin (25 mg BID) and extended-release dipyridamole (200 mg BID)
Study: 1104411
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or azathioprine 100 mg daily (Control)
Study: 1104411
Drug: Prednisone in
Normalized name: Prednisone Intensol
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone in doses given on alternate days and titrated (Pred‐Titrad)
Study: 9663358
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20
Study: 19263664
Drug: Oral washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral washing gel
Study: 8343782
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel ultrasound
Study: 3554085
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (MeCCNU + 5‐FU) + Levamisole
Study: 14641610
Drug: Theophylline 10
Normalized name: theophylline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 10 mg/kg bodyweight
Study: 10377504
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for up to 42 months
Study: 22042247
Drug: 50-μg SS
Normalized name: sennosides, USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-μg SS (scarification of the skin)
Study: 2725453
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg
Study: 11841194
Drug: Cleocin T
Normalized name: Cleocin T
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cleocin T (slightly different gel formulation), indicated for twice-daily use
Study: 30653147
Drug: Pre-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-administration of remifentanil (Group R)
Study: 20501682
Drug: T4 replacement
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 replacement therapy
Study: 27052635
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) for 52 weeks
Study: 10434232
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate vaginal cream
Study: 19273709
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus irinotecan, FU, and leucovorin (IFL)
Study: 19273709
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus fluorouracil and leucovorin (FU/LV)
Study: 9563888
Drug: Capecitabine administered
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered after fasting
Study: 9563888
Drug: Capecitabine administered
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered after food
Study: 28682676
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) (635 nm)
Study: 23695657
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Lutein, 1 mg Zeaxanthin, 100 mg DHA, 30 mg EPA, antioxidants (D1)
Study: 19411393
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly
Study: 16968715
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly and 25 mg twice weekly
Study: 20081039
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg three times per day
Study: 15636035
Drug: Parecoxib preoperatively
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib preoperatively (40 mg IM/IV)
Study: 15636035
Drug: Parecoxib postoperatively
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib postoperatively (40 mg IM/IV)
Study: 11102257
Drug: Low-dose subsegments
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subsegments (<6 Gy)
Study: 23210383
Drug: 16-week Matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week Matrix treatment
Study: 24608864
Drug: Tablet-PC education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-PC education
Study: 28027282
Drug: Rifampin pretreatment
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin pretreatment (20 mg/kg) with ceftriaxone
Study: 1642879
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (vinblastine, mitomycin, cisplatin, and bleomycin) and radiotherapy
Study: 1642879
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy (cisplatin and bleomycin) and radiotherapy
Study: 2991689
Drug: ACTH4-9 analog
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACTH4-9 analog (Org2766) 40 mg/day
Study: 17244834
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with contextualized intervention strategy (reinforced counseling, improved communication, decentralization of treatment, choice of DOT supporter, reinforcement of supervision activities)
Study: 2905252
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 75 mg twice daily
Study: 2908751
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg post cenam nocte
Study: 30202872
Drug: Intensive MDA
Normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive MDA (quarterly single-dose praziquantel plus albendazole daily for 3 days)
Study: 27825272
Drug: Purified urinary
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified urinary FSH starting with a dose of 75 IU
Study: 9095564
Drug: One 20
Normalized name: DIMETHICONE 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 20 mg controlled-release oxycodone tablet
Study: 27159505
Drug: Rifapentine (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (approximately 7.5 mg/kg) plus moxifloxacin
Study: 8759069
Drug: Poloxamer 188
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer 188 (RheothRx) infusion for 48 hours
Study: 1759572
Drug: Defibrinogenation (DF)
Normalized name: DF-1001
DrugBank: DF-1001 (DB18231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrinogenation (DF) therapy
Study: 27170466
Drug: Estradiol (1
Normalized name: fluoroestradiol (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (1 mg/day)
Study: 27198187
Drug: Medium mycoprotein
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium mycoprotein (88 g)
Study: 27198187
Drug: High mycoprotein
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mycoprotein (132 g)
Study: 11695209
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel
Study: 29038320
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (booster dose at 4 years of age)
Study: 22739141
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxaparin sodium (1 mg/kg)
Study: 15665549
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times a day for 2 months
Study: 326301
Drug: Topical atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atenolol (1%, 2%, and 4%)
Study: 25149179
Drug: Prednisone (PN)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PN) 25 mg
Study: 25149179
Drug: Methylprednisolone (MPONE)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPONE) 20 mg
Study: 15881479
Drug: Gatifloxacin 0.3%
Normalized name: GATIFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 0.3% ophthalmic solution
Study: 1680266
Drug: Midazolam 4-5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 4-5 mg, intramuscularly
Study: 18460563
Drug: GH infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH infusion (45 ng/kg.min, 5.5 h)
Study: 17070267
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nociceptin/orphanin FQ in 10 cc saline
Study: 2660992
Drug: SR IS-5-MN
Normalized name: IS 5-MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SR IS-5-MN 50 mg
Study: 21959822
Drug: Garlic (KWAI)
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (KWAI) 300 mg thrice daily + Metformin 500 mg twice daily
Study: 26551263
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of velpatasvir once daily
Study: 1928883
Drug: Hyperbaric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric treatment (simulated descent of 1,432 m (4,600 ft) in a hyperbaric chamber pressurized to 120 mm Hg (2.3 PSI) above ambient pressure)
Study: 24721334
Drug: Functional rehabilitation
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional rehabilitation (control; n=20) intervention practicing the same daily tasks with a therapist's demonstration and guidance
Study: 14687523
Drug: Jing Wan
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jing Wan Hong ointment
Study: 6762247
Drug: Intrapleural BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural BCG plus oral isoniazid (INH)
Study: 18544981
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with hormones
Study: 16340187
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg by rectiole, followed by 10 mg tablets twice daily for 3 days
Study: 11463010
Drug: Incidence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidence of recurrence after discontinuation of treatment
Study: 31525422
Drug: Porcine small
Normalized name: porcine small intestine mucosa lymph follicle preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine small intestine submucosa patch
Study: 8906519
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cilazapril
Study: 7903137
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of whole blood tested negative for HIV antibodies
Study: 12867218
Drug: IM haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM haloperidol 7.5 mg
Study: 22691922
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) 43 g daily for 12 weeks
Study: 19906761
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² plus Epirubicin 75 mg/m² (DE)
Study: 28411872
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg risankizumab
Study: 19335746
Drug: ET receptor
Normalized name: P2Y12 G-protein-coupled platelet receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET receptor antagonists (ETRAs)
Study: 18649561
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel
Study: 9602960
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium (25 mg)
Study: 9602960
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium (50 mg)
Study: 20128823
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily
Study: 8494650
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of almagate (1.5 g, po)
Study: 25135124
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of oral melatonin
Study: 22007026
Drug: Multifactorial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial treatment (lifestyle and drug, including atorvastatin)
Study: 10522578
Drug: mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 1% with 10 ml saline
Study: 31407629
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment
Study: 23904282
Drug: Leptin administration
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin administration
Study: 21513078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with tidal volume of 10 ml kg(‐1).
Study: 8862681
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of cisplatin
Study: 1712735
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 5,000 IU hCG
Study: 1712735
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 5,000 IU hCG
Study: 9243350
Drug: Cyclosporin G
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin G (CSG)
Study: 22424025
Drug: Dalcetrapib 900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 900 mg
Study: 16427490
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 80 mg methylprednisolone acetate and 10 mg bupivacaine
Study: 8482993
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control group)
Study: 18043999
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg
Study: 25517204
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mirtazapine daily for 8 weeks
Study: 29690736
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment)
Study: 28617530
Drug: Non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment group (no folic acid and vitamin B12)
Study: 3358819
Drug: Alcohol intervention
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intervention (mean serum ethanol concentration 93 mg/100 ml, S.D. 17)
Study: 3050006
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy for 7 days
Study: 31965678
Drug: Intralesional methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional methotrexate (MTX) 2 mg/ml
Study: 9358933
Drug: Cytotoxic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic treatment
Study: 22005905
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of 0.5% hyperbaric bupivacaine combined with 2.5 μg sufentanil (Group II)
Study: 12624696
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron orally plus 8 mg dexamethasone intravenously
Study: 28791820
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of botulinum toxin type A (group II)
Study: 9256142
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream
Study: 16130506
Drug: Calcium salts
Normalized name: lonazolac calcium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium salts and vitamin D3 supplements alone
Study: 26347110
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after each chemotherapy infusion.
Study: 19815876
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) at 0.5 mg/kg
Study: 19815876
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) at 1 mg/kg
Study: 7816517
Drug: Intravenous fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fructose (200 mg/kg, 20% solution, 2.5 min)
Study: 24663049
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) 50 mg/m²/d for 10 days
Study: 24663049
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) 50 mg/m²/d for 10 days + entinostat 4 mg/m²/d on day 3 and day 10
Study: 16834487
Drug: Selective DA
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective DA D2 receptor antagonist
Study: 28722627
Drug: Rapid Diagnostic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Diagnostic Tests (RDTs) performed by Community Health Workers (CHWs) for malaria screening and treatment with artemether‐lumefantrine.
Study: 19466436
Drug: Complex cream
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex cream
Study: 31894491
Drug: Teriparatide followed
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide followed by alendronate (once-weekly subcutaneous injections of teriparatide 56.5 μg for 72 weeks followed by alendronate for 48 weeks)
Study: 31894491
Drug: Alendronate monotherapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate monotherapy (alendronate for 120 weeks)
Study: 18470667
Drug: Alendronate monotherapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate monotherapy
Study: 30509312
Drug: Pembrolizumab (anti-PD-1)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (anti-PD-1) plus chemotherapy
Study: 20028833
Drug: 12-week cognitive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week cognitive behavior therapy program for hostility reduction
Study: 6312461
Drug: pivampicillin alone
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivampicillin alone (250 mg pivampicillin 3-times daily for 7 to 14 days)
Study: 9097275
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment for 6 months (Group I)